The model is based on the original 4T1 breast cancer cell line and two genetically edited versions of it—one with biallelic CRISPR/Cas9‐mediated Car9 inactivation and another with constitutively expressed Car9, thus ensuring negative and positive controls for CAIX production in the model system, respectively. This evidence concerns the gene CA9 and breast carcinoma.